Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
A German study published in The Annals of Thoracic Surgery suggests that surgical removal of breast cancer metastases that affect a small part of the lungs may help women live longer.
A large study looking at a 33-year time span found that young women were the only age group to show an increase in metastatic breast cancer as an initial diagnosis.
Talking about end-of-life wishes soon after a metastatic cancer diagnosis may lead to less aggressive, and potentially more comfortable, treatment in the last month of life, a recent analysis showed.
Women with HER2 positive metastatic breast cancer whose cancer grows despite other standard therapies have a new treatment option available next month, now that the Food and Drug Administration approved the EMILIA study’s T-DM1.
NEW YORK (Reuters Health) - More young women are being diagnosed with advanced, metastatic breast cancer than were three decades ago, a new study suggests - although the overall rate of cancers in that group is still small.
(Reuters) - U.S. health regulators approved a new drug made by Roche Holding AG for some patients with late-stage metastatic breast cancer who fail to respond to other therapies.
An article in the New England Journal of Medicine with updated overall survival results from the international EMILIA study of T-DM1 was published two days following an announcement of accelerated FDA review for the medicine.
Findings from the CONFIRM clinical trial presented at the 2012 San Antonio Breast Cancer Symposium in December showed that increasing the dose of fulvestrant (Faslodex) from 250 mg to 500 mg for women with estrogen receptor-positive metastatic breast cancer increased median overall survival by 4.1 months. Overall survival is the time a person lives from the start of treatment until death from any cause.
In a study published in The New England Journal of Medicine, researchers suggest that anastrozole (Arimidex), taken in combination with fulvestrant (Faslodex), extends both progression-free and overall survival in hormone receptor-positive metastatic breast cancer.
A final data analysis of the study EGF104900, which compared lapatinib (Tykerb) plus trastuzumab (Herceptin) to lapatinib alone, found the combination therapy resulted in a significant increase in overall survival in women with HER2 positive metastatic breast cancer.